One in Three Rheumatologists View BMSâ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data
The FDA's upcoming decision on Sotyktu could impact Bristol-Myers Squibb's market position in psoriatic arthritis treatment, reflecting rheumatologist...
Read Full Article →